REVIVA PHARMACEUTICALS HOLDINGS, INC.

Tenzing Acquisition Corp, listed under the ticker TZAC, is a blank-check company that completed its initial public offering in 2018 with a strategic focus on the life sciences and biopharmaceutical sector. The company filed an 8-K with the SEC on August 24, 2018, bearing accession number 0001144204-18-046269, in connection with its proposed business combination with Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical firm developing treatments for central nervous system and metabolic disorders. The filing reflects material activity during the de-SPAC process as Tenzing Acquisition Corp advanced toward completing the merger. For full filing history, sponsor data, and deal analytics on TZAC and hundreds of other SPACs, sign up for complete access at SpacDesk.